Total Payments
$629,493
2024 Payments
$139,367
Companies
48
Transactions
1,311
Payment Breakdown by Category
Other$439,394 (69.8%)
Travel$70,427 (11.2%)
Consulting$66,817 (10.6%)
Food & Beverage$26,912 (4.3%)
Research$25,771 (4.1%)
Education$171.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $431,804 | 155 | 68.6% |
| Travel and Lodging | $70,427 | 355 | 11.2% |
| Consulting Fee | $66,817 | 20 | 10.6% |
| Food and Beverage | $26,912 | 732 | 4.3% |
| Unspecified | $25,771 | 43 | 4.1% |
| Honoraria | $7,590 | 3 | 1.2% |
| Education | $171.94 | 3 | 0.0% |
Payments by Type
General
$603,722
1,268 transactions
Research
$25,771
43 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $213,447 | 264 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $180,748 | 294 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $73,730 | 188 | $0 (2024) |
| Optinose US, Inc. | $32,858 | 68 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $27,652 | 55 | $0 (2023) |
| Merck Sharp & Dohme LLC | $22,216 | 22 | $0 (2023) |
| Glenmark Pharmaceuticals Inc. | $18,903 | 8 | $0 (2017) |
| Hikma Pharmaceuticals USA | $14,187 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $13,697 | 46 | $0 (2024) |
| ALK-Abello, Inc | $12,407 | 44 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $139,367 | 187 | AstraZeneca Pharmaceuticals LP ($56,995) |
| 2023 | $101,297 | 184 | GENZYME CORPORATION ($45,641) |
| 2022 | $81,721 | 154 | GENZYME CORPORATION ($39,711) |
| 2021 | $70,508 | 162 | Regeneron Healthcare Solutions, Inc. ($20,068) |
| 2020 | $27,070 | 110 | Regeneron Healthcare Solutions, Inc. ($10,772) |
| 2019 | $74,132 | 169 | Regeneron Healthcare Solutions, Inc. ($26,341) |
| 2018 | $56,092 | 180 | GENZYME CORPORATION ($17,253) |
| 2017 | $79,306 | 165 | GENZYME CORPORATION ($27,258) |
All Payment Transactions
1,311 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: Immunology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | CSL Behring | Hizentra (Biological), Privigen | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Immunology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.58 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $105.61 | General |
| Category: Immunology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: Immunology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $16.62 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Respiratory | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $17.40 | General |
| Category: Respiratory | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $195.70 | General |
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $174.27 | General |
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $24.92 | General |
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $20.99 | General |
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $14.90 | General |
| 11/15/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $178.19 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $18,903 | 8 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intra | SANOFI-AVENTIS U.S. LLC | $1,530 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 | SANOFI US SERVICES INC. | $1,331 | 16 |
| A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $1,250 | 1 |
| Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are nave to, Intolerant of, or Incomplete Responders to Om | SANOFI US SERVICES INC. | $1,047 | 10 |
| Insmed BIRCH Study | Insmed, Inc. | $959.93 | 4 |
| A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids | GENZYME CORPORATION | $750.00 | 2 |
About Dr. Gary Gross, MD
Dr. Gary Gross, MD is a Allergy healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285601336.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Gross, MD has received a total of $629,493 in payments from pharmaceutical and medical device companies, with $139,367 received in 2024. These payments were reported across 1,311 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($431,804).
Ad
Practice Information
- Specialty Allergy
- Location Dallas, TX
- Active Since 03/07/2006
- Last Updated 07/08/2007
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1285601336
Products in Payments
- DUPIXENT (Biological) $269,678
- AIRSUPRA (Drug) $60,214
- DUPIXENT (Drug) $41,703
- DUPIXENT DUPILUMAB INJECTION (Biological) $38,254
- Xhance (Drug) $32,831
- ATOPIC DERMATITIS - DISEASE (Drug) $27,198
- Ryaltris (Drug) $14,187
- Odactra (Drug) $12,030
- ArmonAir Digihaler (Drug) $11,323
- XOLAIR (Biological) $7,171
- QVAR (Drug) $6,952
- FASENRA (Drug) $6,305
- FASENRA (Biological) $5,349
- AIRDUO (Drug) $4,141
- ProAir Digihaler (Drug) $3,582
- SAR440340 (Drug) $1,331
- PROAIR (Drug) $761.31
- ALVESCO (Drug) $641.69
- Auvi-Q (Drug) $511.25
- PROAIR RESPICLICK (Drug) $500.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy Doctors in Dallas
Dr. Sandeep Gupta, M.d, M.D
Allergy — Payments: $15,830
Allergy $15,830
Mr. Michael Ruff, Md, MD
Allergy — Payments: $8,871
Allergy $8,871
Erin Clarke, Md, MD
Allergy — Payments: $6,245
Allergy $6,245
Christina Huddleston, M.d, M.D
Allergy — Payments: $4,963
Allergy $4,963
Tran Ly, Md, MD
Allergy — Payments: $3,606
Allergy $3,606
Allan Gilbert, Md, MD
Allergy
Allergy